GWPH - GW Pharma's Epidyolex OK'd in Europe for seizures due to rare genetic condition

The European Commission has approved GW Pharmaceuticals' (GWPH) Type II variation application for EPIDYOLEX (cannabidiol) as an adjunctive treatment of seizures associated with tuberous sclerosis complex((TSC)), for patients two years of age and older.TSC, a rare genetic condition, mostly causes benign tumours to grow in vital organs of the body, and in which epilepsy is the most common neurological feature. The approval is based on data from a positive Phase 3 safety and efficacy study evaluating 25 mg/kg/day of GW’s cannabidiol.This approval represents the third indication for GW’s cannabidiol in Europe.

For further details see:

GW Pharma's Epidyolex OK'd in Europe for seizures due to rare genetic condition